Company intelligence / Profile preview

Indalo Therapeutics

St. Louis, Missouri, USA6sense.com ↗

Ownership: Private
Development stage: Preclinical

Overview

IDL‑2965 has completed a Phase I clinical trial evaluating safety, tolerability, and pharmacokinetics in healthy subjects and patients with idiopathic pulmonary fibrosis. The study aimed to provide data supporting further development in fibrotic indications such as NASH and IPF. No detailed efficacy results are publicly available yet.

Therapeutic areas: GastroenterologyPulmonology
Modalities: Small molecules (specifically integrin antagonists)
Industry: Biotech

Drug pipeline

1 asset

idl-2965

Partnerships

No major pharma partnerships disclosed.

Beyond the preview

Go deeper on Indalo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Indalo Therapeutics.

Explore the full profile